市場調查報告書
商品編碼
1006300

非專利注射劑的全球市場:各分子類型,各產品類型,各流通管道,各給藥途徑,各應用領域,各地區的,市場規模調查與預測(2020年∼2027年)

Global Generic Injectable Market Size study, by Product type by Molecule Type by Application by Route of Administration by Distribution channel and Regional Forecasts 2020-2027.

出版日期: | 出版商: Bizwit Research & Consulting LLP | 英文 | 商品交期: 2-3個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

全球非專利注射劑的市場規模在2019年估算為約307億2,000萬美金,在2020年∼2027年間的預測期間內,預計將以10%以上健全的成長率增長。

由於慢性病的日益流行,仿製藥的研究和開發正在取得進展。靜脈內 (IV) 和肌肉內 (IM) 給藥越來越受歡迎,以響應對緊急治療替代方案的需求。

這份報告提供非專利注射劑的世界市場調查,提供市場概要,市場成長要素及阻礙因素分析,市場機會,分子類型·產品類型·流通管道·給藥途徑·應用·各地區的市場規模的變化與預測,競爭情形,主要企業的簡介等系統性資訊。

目錄

第1章 摘要整理

第2章 市場定義和範圍

第3章 市場動態

  • 市場影響分析(2018年∼2027年)

第4章 產業分析

  • 波特的五力分析
  • PEST分析
  • 投資採用模式
  • 分析師的推薦事項與結論

第5章 各產品類型

  • 市場概述
  • 效能:潛在的分析
  • 市場規模預測:2017年∼2027年(10億美元單位)
  • 子區隔分析
    • 單株抗體
    • 免疫球蛋白非專利注射劑
    • 胰島素非專利注射劑
    • 血液因子非專利注射劑
    • 肰抗生素非專利注射劑
    • 疫苗非專利注射劑
    • 化療劑非專利注射劑
    • 其他

第6章 各分子類型

  • 市場概述
  • 效能:潛在的分析
  • 市場規模預測:2017年∼2027年(10億美元單位)
  • 子區隔分析
    • 低分子非專利注射劑
    • 大分子非專利注射劑

第7章 各應用領域

  • 市場概述
  • 效能:潛在的分析
  • 市場規模預測:2017年∼2027年(10億美元單位)
  • 子區隔分析
    • 腫瘤學
    • 感染疾病
    • 糖尿病
    • 血液疾病
    • 中樞神經系統疾病
    • 心血管疾病
    • 其他

第8章 各給藥途徑

  • 市場概述
  • 效能:潛在的分析
  • 市場規模預測:2017年∼2027年(10億美元單位)
  • 子區隔分析
    • 靜脈(IV)非專利注射劑
    • 肌肉內(IM)非專利注射劑
    • 皮下(SC)非專利注射劑

第9章 各流通管道

  • 市場概述
  • 效能:潛在的分析
  • 市場規模預測:2017年∼2027年(10億美元單位)
  • 子區隔分析
    • 醫院藥局
    • 零售藥局
    • 藥妝店
    • 線上藥局

第10章 各地區

  • 地區市場概述
  • 北美
    • 美國
    • 加拿大
  • 歐洲的概述
    • 英國
    • 德國
    • 法國
    • 西班牙
    • 義大利
    • 其他歐洲
  • 亞太地區的概述
    • 中國
    • 印度
    • 日本
    • 澳洲
    • 韓國
    • 其他亞太地區
  • 南美的概述
    • 巴西
    • 墨西哥
  • 其他地區

第11章 競爭資訊

  • 頂級市場策略
  • 企業簡介
    • Samsung Biologics Co Ltd
    • Aurobindo Pharma Limited
    • Sun Pharmaceutical Industries Ltd.
    • Novartis AG
    • Merck & Co. Inc.
    • Cipla Ltd
    • Pfizer Inc
    • Fresenius Kabi
    • Sanofi S.A
    • AstraZeneca Plc

第12章 調查流程

目錄

Global Generic Injectable Market is valued approximately USD 30.72 billion in 2019 and is anticipated to grow with a healthy growth rate of more than 10 % over the forecast period 2020-2027. Generic injectables are bioequivalents of branded injectables and are not secured under medication patents. Since they have the same active ingredient, dose, strength, consistency, and type as the innovator drugs, they are both safe and efficient. While generic injectables are more difficult to manufacture, their research and development period is less expensive and shorter. Generic drug makers, unlike branded drug producers, do not need to invest millions of dollars in R&D and marketing. Furthermore, as opposed to oral generics, the number of entrants in the generic injectables industry is smaller, resulting in less price deflation and greater profit margins. The rising prevalence of chronic diseases has prompted developments in generic injectables research and development. The popularity of intravenous (IV) and intramuscular (IM) drug administration has grown in response to the need for urgent care alternatives. Insulin, for example, is best administered intramuscularly (IM). Generic injectable medicines have a range of benefits, including quicker licenses, more biologic medications in production pipelines, and a greater demand for injectable medication delivery. Drug sales opportunities for vaccinations, monoclonal antibodies, peptides, immunoglobulins, and antibodies are being bolstered by factors such as cost-effectiveness and improved health outcomes. Generic injectables are now becoming more widely accepted as more cost-effective drugs than their branded counterparts. Adoption rates for generic injectables are increasing as a result of these trends. A variety of causes, including family medical history, obesity, among others, are contributing to an increase in the prevalence of lifestyle-related diseases such as diabetes in both developed and developing countries. The rising incidence of diabetes raises medical costs associated with its treatment. According to WHO statistics, the prevalence of diabetes is projected to grow from 117 million in 2000 to 422.0 million in 2030, owing to an increase in patient numbers. Diabetes prevalence was calculated to be 2.8 percent in all age ranges in 2000, and is expected to increase to 4.4 percent by 2030. Additionally, the expiration of branded item patents and a decrease in the number of new product releases have benefited generic drugs and led to the growth of industry participants and product prices. As compared to the prices of premium drugs, generic injectables are comparatively inexpensive, giving a substantial boost to demand growth and still the net profits. Pfizer announced in July 2020 that it had reached an agreement to commit about US$ 465 million to the construction of a sterile injectable plant in Portage, Michigan. This growth is part of the company's strategy to spend about $5 billion in each U.S.-based capital challenge in order to keep up with developments in the country's corporate evaluation. However, manufacturing generic injectables necessitates sophisticated machinery, both of which must meet stringent registration and sterilisation requirements for - batch prior to output. Owing to the purchase/rent-to-lease of fixed assets, which results in high running expenses and debt ratios. Furthermore, compliance costs are considerably higher as a result of FDA requirements that high levels of safety be maintained not only throughout the production process, but also during processing, transportation, and delivery. This impedes the growth of the market over the forecast period of 2020-2027. Although, the expansion of large molecule products into injectables are fueling developments presenting a lucrative opportunity for the market.

The main regions of Asia Pacific, North America, Europe, Latin America, and the Rest of the World are included in the geographical study of the global Generic Injectable market. North America is the leading region across the world in terms of market share owing to the well-established infrastructure and rising R&D expenditure. Whereas, Asia-Pacific is also anticipated to exhibit highest growth rate over the forecast period 2020-2027. Factors such as growth of government spending in pharmaceutical sectors would create lucrative growth prospects for the Generic Injectable market across Asia-Pacific region.

Major market player included in this report are:

Samsung Biologics Co Ltd

Aurobindo Pharma Limited

Sun Pharmaceutical Industries Ltd.

Novartis AG

Merck & Co. Inc.

Cipla Ltd

Pfizer Inc

Fresenius Kabi

Sanofi S.A

AstraZeneca Plc

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Product type:

Monoclonal Antibodies

Immunoglobulin Generic injectable

Insulin Generic injectable

Blood Factors Generic injectable

Peptide Antibiotics Generic injectable

Vaccines Generic injectable

Chemotherapy Agents Generic injectable

Others

By Molecule Type:

Small Molecule Generic injectable

Large Molecule Generic injectable

By Application:

Oncology

Infectious Diseases

Diabetes

Blood Disorders

CNS Diseases

Cardiovascular Diseases

Others

By Route of Administration:

Intravenous (IV) Generic injectable

Intramuscular (IM) Generic injectable

Subcutaneous (SC) Generic injectable

By Distribution channel:

Hospital Pharmacies

Retail Pharmacies

Drug Stores

Online Pharmacies

By Region:

North America

U.S.

Canada

Europe

UK

Germany

France

Spain

Italy

ROE

Asia Pacific

China

India

Japan

Australia

South Korea

RoAPAC

Latin America

Brazil

Mexico

Rest of the World

Furthermore, years considered for the study are as follows:

Historical year - 2017, 2018

Base year - 2019

Forecast period - 2020 to 2027

Target Audience of the Global Generic Injectable Market in Market Study:

Key Consulting Companies & Advisors

Large, medium-sized, and small enterprises

Venture capitalists

Value-Added Resellers (VARs)

Third-party knowledge providers

Investment bankers

Investors

Table of Contents

Chapter 1. Executive Summary

  • 1.1. Market Snapshot
  • 1.2. Global & Segmental Market Estimates & Forecasts, 2018-2027 (USD Billion)
    • 1.2.1. Generic Injectable Market, by Region, 2018-2027 (USD Billion)
    • 1.2.2. Generic Injectable Market, by Product Type, 2018-2027 (USD Billion)
    • 1.2.3. Generic Injectable Market, by Molecule Type, 2018-2027 (USD Billion)
    • 1.2.4. Generic Injectable Market, by Application, 2018-2027 (USD Billion)
    • 1.2.5. Generic Injectable Market, by Route of Administration, 2018-2027 (USD Billion)
    • 1.2.6. Generic Injectable Market, by Distribution Channel, 2018-2027 (USD Billion)
  • 1.3. Key Trends
  • 1.4. Estimation Methodology
  • 1.5. Research Assumption

Chapter 2. Global Generic Injectable Market Definition and Scope

  • 2.1. Objective of the Study
  • 2.2. Market Definition & Scope
    • 2.2.1. Scope of the Study
    • 2.2.2. Industry Evolution
  • 2.3. Years Considered for the Study
  • 2.4. Currency Conversion Rates

Chapter 3. Global Generic Injectable Market Dynamics

  • 3.1. Generic Injectable Market Impact Analysis (2018-2027)
    • 3.1.1. Market Drivers
      • 3.1.1.1. Rising prevalence of chronic diseases
      • 3.1.1.2. The expiration of branded item patents and a decrease in the number of new product releases
    • 3.1.2. Market Challenges
      • 3.1.2.1. Complex manufacturing of generic injectables
      • 3.1.2.2. Rising stringent regulation
    • 3.1.3. Market Opportunities
      • 3.1.3.1. Expansion of large molecule products into injectables
      • 3.1.3.2. Investments on manufacturing capabilities by emerging countries

Chapter 4. Global Generic Injectable Market Industry Analysis

  • 4.1. Porter's 5 Force Model
    • 4.1.1. Bargaining Power of Suppliers
    • 4.1.2. Bargaining Power of Buyers
    • 4.1.3. Threat of New Entrants
    • 4.1.4. Threat of Substitutes
    • 4.1.5. Competitive Rivalry
    • 4.1.6. Futuristic Approach to Porter's 5 Force Model (2017-2027)
  • 4.2. PEST Analysis
    • 4.2.1. Political
    • 4.2.2. Economical
    • 4.2.3. Social
    • 4.2.4. Technological
  • 4.3. Investment Adoption Model
  • 4.4. Analyst Recommendation & Conclusion

Chapter 5. Global Generic Injectable Market, by Product Type

  • 5.1. Market Snapshot
  • 5.2. Global Generic Injectable Market by Product Type, Performance - Potential Analysis
  • 5.3. Global Generic Injectable Market Estimates & Forecasts by Product Type 2017-2027 (USD Billion)
  • 5.4. Generic Injectable Market, Sub Segment Analysis
    • 5.4.1. Monoclonal Antibodies
    • 5.4.2. Immunoglobulin Generic injectable
    • 5.4.3. Insulin Generic injectable
    • 5.4.4. Blood Factors Generic injectable
    • 5.4.5. Peptide Antibiotics Generic injectable
    • 5.4.6. Vaccines Generic injectable
    • 5.4.7. Chemotherapy Agents Generic injectable
    • 5.4.8. Others

Chapter 6. Global Generic Injectable Market, by Molecule Type

  • 6.1. Market Snapshot
  • 6.2. Global Generic Injectable Market by Molecule Type, Performance - Potential Analysis
  • 6.3. Global Generic Injectable Market Estimates & Forecasts by Molecule Type 2017-2027 (USD Billion)
  • 6.4. Generic Injectable Market, Sub Segment Analysis
    • 6.4.1. Small Molecule Generic injectable
    • 6.4.2. Large Molecule Generic injectable

Chapter 7. Global Generic Injectable Market, by Application

  • 7.1. Market Snapshot
  • 7.2. Global Generic Injectable Market by Application, Performance - Potential Analysis
  • 7.3. Global Generic Injectable Market Estimates & Forecasts by Application 2017-2027 (USD Billion)
  • 7.4. Generic Injectable Market, Sub Segment Analysis
    • 7.4.1. Oncology
    • 7.4.2. Infectious Diseases
    • 7.4.3. Diabetes
    • 7.4.4. Blood Disorders
    • 7.4.5. CNS Diseases
    • 7.4.6. Cardiovascular Diseases
    • 7.4.7. Others

Chapter 8. Global Generic Injectable Market, by Route of Administration

  • 8.1. Market Snapshot
  • 8.2. Global Generic Injectable Market by Route of Administration, Performance - Potential Analysis
  • 8.3. Global Generic Injectable Market Estimates & Forecasts by Route of Administration 2017-2027 (USD Billion)
  • 8.4. Generic Injectable Market, Sub Segment Analysis
    • 8.4.1. Intravenous (IV) Generic injectable
    • 8.4.2. Intramuscular (IM) Generic injectable
    • 8.4.3. Subcutaneous (SC) Generic injectable

Chapter 9. Global Generic Injectable Market, by Distribution Channel

  • 9.1. Market Snapshot
  • 9.2. Global Generic Injectable Market by Distribution Channel, Performance - Potential Analysis
  • 9.3. Global Generic Injectable Market Estimates & Forecasts by Distribution Channel 2017-2027 (USD Billion)
  • 9.4. Generic Injectable Market, Sub Segment Analysis
    • 9.4.1. Hospital Pharmacies
    • 9.4.2. Retail Pharmacies
    • 9.4.3. Drug Stores
    • 9.4.4. Online Pharmacies

Chapter 10. Global Generic Injectable Market, Regional Analysis

  • 10.1. Generic Injectable Market, Regional Market Snapshot
  • 10.2. North America Generic Injectable Market
    • 10.2.1. U.S. Generic Injectable Market
      • 10.2.1.1. Product Type breakdown estimates & forecasts, 2017-2027
      • 10.2.1.2. Molecule Type breakdown estimates & forecasts, 2017-2027
      • 10.2.1.3. Application breakdown estimates & forecasts, 2017-2027
      • 10.2.1.4. Route of Administration breakdown estimates & forecasts, 2017-2027
      • 10.2.1.5. Distribution Channel breakdown estimates & forecasts, 2017-2027
    • 10.2.2. Canada Generic Injectable Market
  • 10.3. Europe Generic Injectable Market Snapshot
    • 10.3.1. U.K. Generic Injectable Market
    • 10.3.2. Germany Generic Injectable Market
    • 10.3.3. France Generic Injectable Market
    • 10.3.4. Spain Generic Injectable Market
    • 10.3.5. Italy Generic Injectable Market
    • 10.3.6. Rest of Europe Generic Injectable Market
  • 10.4. Asia-Pacific Generic Injectable Market Snapshot
    • 10.4.1. China Generic Injectable Market
    • 10.4.2. India Generic Injectable Market
    • 10.4.3. Japan Generic Injectable Market
    • 10.4.4. Australia Generic Injectable Market
    • 10.4.5. South Korea Generic Injectable Market
    • 10.4.6. Rest of Asia Pacific Generic Injectable Market
  • 10.5. Latin America Generic Injectable Market Snapshot
    • 10.5.1. Brazil Generic Injectable Market
    • 10.5.2. Mexico Generic Injectable Market
  • 10.6. Rest of The World Generic Injectable Market

Chapter 11. Competitive Intelligence

  • 11.1. Top Market Strategies
  • 11.2. Company Profiles
    • 11.2.1. Samsung Biologics Co Ltd
      • 11.2.1.1. Key Information
      • 11.2.1.2. Overview
      • 11.2.1.3. Financial (Subject to Data Availability)
      • 11.2.1.4. Product Summary
      • 11.2.1.5. Recent Developments
    • 11.2.2. Aurobindo Pharma Limited
    • 11.2.3. Sun Pharmaceutical Industries Ltd.
    • 11.2.4. Novartis AG
    • 11.2.5. Merck & Co. Inc.
    • 11.2.6. Cipla Ltd
    • 11.2.7. Pfizer Inc
    • 11.2.8. Fresenius Kabi
    • 11.2.9. Sanofi S.A
    • 11.2.10. AstraZeneca Plc

Chapter 12. Research Process

  • 12.1. Research Process
    • 12.1.1. Data Mining
    • 12.1.2. Analysis
    • 12.1.3. Market Estimation
    • 12.1.4. Validation
    • 12.1.5. Publishing
  • 12.2. Research Attributes
  • 12.3. Research Assumption

LIST OF TABLES

  • TABLE 1. Global Generic Injectable market, report scope
  • TABLE 2. Global Generic Injectable market estimates & forecasts by Region 2017-2027 (USD Billion)
  • TABLE 3. Global Generic Injectable market estimates & forecasts by Product Type 2017-2027 (USD Billion)
  • TABLE 4. Global Generic Injectable market estimates & forecasts by Molecule Type 2017-2027 (USD Billion)
  • TABLE 5. Global Generic Injectable market estimates & forecasts by Application 2017-2027 (USD Billion)
  • TABLE 6. Global Generic Injectable market estimates & forecasts by Route of Administration 2017-2027 (USD Billion)
  • TABLE 7. Global Generic Injectable market estimates & forecasts by Distribution Channel 2017-2027 (USD Billion)
  • TABLE 8. Global Generic Injectable market by segment, estimates & forecasts, 2017-2027 (USD Billion)
  • TABLE 9. Global Generic Injectable market by region, estimates & forecasts, 2017-2027 (USD Billion)
  • TABLE 10. Global Generic Injectable market by segment, estimates & forecasts, 2017-2027 (USD Billion)
  • TABLE 11. Global Generic Injectable market by region, estimates & forecasts, 2017-2027 (USD Billion)
  • TABLE 12. Global Generic Injectable market by segment, estimates & forecasts, 2017-2027 (USD Billion)
  • TABLE 13. Global Generic Injectable market by region, estimates & forecasts, 2017-2027 (USD Billion)
  • TABLE 14. Global Generic Injectable market by segment, estimates & forecasts, 2017-2027 (USD Billion)
  • TABLE 15. Global Generic Injectable market by region, estimates & forecasts, 2017-2027 (USD Billion)
  • TABLE 16. Global Generic Injectable market by segment, estimates & forecasts, 2017-2027 (USD Billion)
  • TABLE 17. Global Generic Injectable market by region, estimates & forecasts, 2017-2027 (USD Billion)
  • TABLE 18. U.S. Generic Injectable market estimates & forecasts, 2017-2027 (USD Billion)
  • TABLE 19. U.S. Generic Injectable market estimates & forecasts by segment 2017-2027 (USD Billion)
  • TABLE 20. U.S. Generic Injectable market estimates & forecasts by segment 2017-2027 (USD Billion)
  • TABLE 21. Canada Generic Injectable market estimates & forecasts, 2017-2027 (USD Billion)
  • TABLE 22. Canada Generic Injectable market estimates & forecasts by segment 2017-2027 (USD Billion)
  • TABLE 23. Canada Generic Injectable market estimates & forecasts by segment 2017-2027 (USD Billion)
  • TABLE 24. UK Generic Injectable market estimates & forecasts, 2017-2027 (USD Billion)
  • TABLE 25. UK Generic Injectable market estimates & forecasts by segment 2017-2027 (USD Billion)
  • TABLE 26. UK Generic Injectable market estimates & forecasts by segment 2017-2027 (USD Billion)
  • TABLE 27. Germany Generic Injectable market estimates & forecasts, 2017-2027 (USD Billion)
  • TABLE 28. Germany Generic Injectable market estimates & forecasts by segment 2017-2027 (USD Billion)
  • TABLE 29. Germany Generic Injectable market estimates & forecasts by segment 2017-2027 (USD Billion)
  • TABLE 30. RoE Generic Injectable market estimates & forecasts, 2017-2027 (USD Billion)
  • TABLE 31. RoE Generic Injectable market estimates & forecasts by segment 2017-2027 (USD Billion)
  • TABLE 32. RoE Generic Injectable market estimates & forecasts by segment 2017-2027 (USD Billion)
  • TABLE 33. China Generic Injectable market estimates & forecasts, 2017-2027 (USD Billion)
  • TABLE 34. China Generic Injectable market estimates & forecasts by segment 2017-2027 (USD Billion)
  • TABLE 35. China Generic Injectable market estimates & forecasts by segment 2017-2027 (USD Billion)
  • TABLE 36. India Generic Injectable market estimates & forecasts, 2017-2027 (USD Billion)
  • TABLE 37. India Generic Injectable market estimates & forecasts by segment 2017-2027 (USD Billion)
  • TABLE 38. India Generic Injectable market estimates & forecasts by segment 2017-2027 (USD Billion)
  • TABLE 39. Japan Generic Injectable market estimates & forecasts, 2017-2027 (USD Billion)
  • TABLE 40. Japan Generic Injectable market estimates & forecasts by segment 2017-2027 (USD Billion)
  • TABLE 41. Japan Generic Injectable market estimates & forecasts by segment 2017-2027 (USD Billion)
  • TABLE 42. RoAPAC Generic Injectable market estimates & forecasts, 2017-2027 (USD Billion)
  • TABLE 43. RoAPAC Generic Injectable market estimates & forecasts by segment 2017-2027 (USD Billion)
  • TABLE 44. RoAPAC Generic Injectable market estimates & forecasts by segment 2017-2027 (USD Billion)
  • TABLE 45. Brazil Generic Injectable market estimates & forecasts, 2017-2027 (USD Billion)
  • TABLE 46. Brazil Generic Injectable market estimates & forecasts by segment 2017-2027 (USD Billion)
  • TABLE 47. Brazil Generic Injectable market estimates & forecasts by segment 2017-2027 (USD Billion)
  • TABLE 48. Mexico Generic Injectable market estimates & forecasts, 2017-2027 (USD Billion)
  • TABLE 49. Mexico Generic Injectable market estimates & forecasts by segment 2017-2027 (USD Billion)
  • TABLE 50. Mexico Generic Injectable market estimates & forecasts by segment 2017-2027 (USD Billion)
  • TABLE 51. RoLA Generic Injectable market estimates & forecasts, 2017-2027 (USD Billion)
  • TABLE 52. RoLA Generic Injectable market estimates & forecasts by segment 2017-2027 (USD Billion)
  • TABLE 53. RoLA Generic Injectable market estimates & forecasts by segment 2017-2027 (USD Billion)
  • TABLE 54. Row Generic Injectable market estimates & forecasts, 2017-2027 (USD Billion)
  • TABLE 55. Row Generic Injectable market estimates & forecasts by segment 2017-2027 (USD Billion)
  • TABLE 56. Row Generic Injectable market estimates & forecasts by segment 2017-2027 (USD Billion)
  • TABLE 57. List of secondary sources, used in the study of global Generic Injectable market
  • TABLE 58. List of primary sources, used in the study of global Generic Injectable market
  • TABLE 59. Years considered for the study
  • TABLE 60. Exchange rates considered

LIST OF FIGURES

List of figures

  • FIG 1. Global Generic Injectable market, research methodology
  • FIG 2. Global Generic Injectable market, market estimation techniques
  • FIG 3. Global market size estimates & forecast methods
  • FIG 4. Global Generic Injectable market, key trends 2019
  • FIG 5. Global Generic Injectable market, growth prospects 2020-2027
  • FIG 6. Global Generic Injectable market, porters 5 force model
  • FIG 7. Global Generic Injectable market, pest analysis
  • FIG 8. Global Generic Injectable market, value chain analysis
  • FIG 9. Global Generic Injectable market by segment, 2017 & 2027 (USD Billion)
  • FIG 10. Global Generic Injectable market by segment, 2017 & 2027 (USD Billion)
  • FIG 11. Global Generic Injectable market by segment, 2017 & 2027 (USD Billion)
  • FIG 12. Global Generic Injectable market by segment, 2017 & 2027 (USD Billion)
  • FIG 13. Global Generic Injectable market by segment, 2017 & 2027 (USD Billion)
  • FIG 14. Global Generic Injectable market, regional snapshot 2017 & 2027
  • FIG 15. North America Generic Injectable market 2017 & 2027 (USD Billion)
  • FIG 16. Europe Generic Injectable market 2017 & 2027 (USD Billion)
  • FIG 17. Asia pacific Generic Injectable market 2017 & 2027 (USD Billion)
  • FIG 18. Latin America Generic Injectable market 2017 & 2027 (USD Billion)
  • FIG 19. Global Generic Injectable market, company market share analysis (2019)